DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Creon (Amylase / Lipase / Protease) - Summary



CREON is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, proteases, and amylases. Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble or insoluble in alcohol and ether. Each delayed-release capsule for oral administration contains enteric-coated spheres (0.71–1.60 mm in diameter). The active ingredient evaluated in clinical trials is lipase. CREON is dosed by lipase units. Other active ingredients include protease and amylase.

CREON (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. ®

See all Creon indications & dosage >>


Published Studies Related to Creon (Amylase / Lipase / Protease)

Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. [2010.10]
OBJECTIVES: Pancreatic-enzyme replacement therapy (PERT) is the standard of care to prevent maldigestion, malnutrition, and excessive weight loss in patients with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). Our objective was to assess the efficacy and safety of a new formulation of pancrelipase (pancreatin) delayed-release 12,000-lipase unit capsules (CREON) in patients with EPI due to CP or PS... CONCLUSIONS: Pancrelipase delayed-release 12,000-lipase unit capsules were effective in treating fat and nitrogen maldigestion with a TEAE rate similar to that of placebo in patients with EPI due to CP or PS.

Pancrelipase Delayed-Release Capsules (CREON) for Exocrine Pancreatic Insufficiency due to Chronic Pancreatitis or Pancreatic Surgery: A Double-Blind Randomized Trial. [2010.05.25]
CONCLUSIONS:Pancrelipase delayed-release 12,000-lipase unit capsules were effective in treating fat and nitrogen maldigestion with a TEAE rate similar to that of placebo in patients with EPI due to CP or PS.Am J Gastroenterol advance online publication, 25 May 2010; doi:10.1038/ajg.2010.201.

Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. [2009.12]
BACKGROUND: Pancreatic enzyme replacement therapy is critical for adequate nutrition in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI)... CONCLUSIONS: This study demonstrated Creon was effective in treating EPI due to CF and was safe and well tolerated.

The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. [2006.08]
OBJECTIVES: Creon 10 Minimicrospheres is an enteric-coated, delayed-release pancrelipase preparation designed to deliver active pancreatic enzymes to the small intestine. The primary objective of this study was to compare the effect of Creon 10 with placebo in the control of steatorrhea in chronic pancreatitis patients. Secondary objectives included evaluation of stool parameters and global improvement of symptoms scales... CONCLUSIONS: This randomized, placebo-controlled trial found that Creon 10 treatment controlled steatorrhea, as reflected in reduced fat excretion, decreased stool frequency and improved stool consistency. Creon 10 treatment was safe and well tolerated.

Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres--an open randomised crossover preference study. [2002.12]
Creon 10,000 Minimicrospherestrade mark (Creon) 10,000 MMS) is a pancreatic enzyme formulation that contains smaller spheres of pancreatin in a 50% smaller capsule than conventional microspheres (Creon) 8,000)...

more studies >>

Clinical Trials Related to Creon (Amylase / Lipase / Protease)

Assessment of Insulin Production From Native Pancreas in Patients With Pancreas Transplants [Completed]
This study will examine whether insulin-producing cells in the pancreas (beta cells) can recover in patients with type 1 diabetes who have had a pancreas transplant. In type 1 diabetes, the body's immune system destroys the beta cells. Patients are treated with insulin shots or a pancreas transplant to control their blood sugar. Some experiments suggest that the pancreas may have the capacity to recover some of its insulin-producing capacity, but that ability is negated by factors such as the continuing immune attack and erratic blood sugar levels in patients.

Patients who have had a pancreas transplant may be in a unique situation to allow their own pancreas to regrow beta cells for two reasons: 1) the medicines they take to prevent rejection of the transplanted pancreas weaken their immune system; and 2) they have near-normal blood sugar levels because of their functioning transplanted pancreas. This study will test this hypothesis by sampling blood from patients' hepatic vein, which drains the liver and native pancreas and from their iliac vein, which drains the transplanted pancreas. This will determine whether insulin is coming from the transplanted pancreas (iliac vein) or the liver and native pancreas (hepatic vein).

Patients 18 years of age and older who have had stable pancreatic transplant function for more than 5 years may be eligible for this study. Candidates are screened with a medical history and physical examination.

Participants are admitted to the hospital for 2 days for a full medical examination, blood tests and procedures to determine insulin production. The procedures will include the placement of catheters in the neck and groin for blood sampling. Participants will be closely monitored after the procedures and discharged home if there are no complications.

Viokase 16, Viokase16 Plus Nexium and Nexium Alone [Recruiting]
Our primary hypothesis is that the addition of Nexium to Viokase 16 will decrease the chronic abdominal pain in patients with small duct chronic pancreatitis in a superior fashion compared to Viokase 16 plus placebo or to Nexium alone. A secondary hypothesis would be an increase in quality of life. Our objective is to elucidate the role of Nexium in the control of pancreatic pain, quality of life, and narcotic usage alone or when added to Viokase 16. Our endpoints are the reduction of abdominal pain, decreased pain medication usage, decreased ER visits and decreased hospital admissions for abdominal pain.

A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids [Recruiting]
Experience with tacrolimus in pancreas transplantation has become a standard for immunosuppression in almost all pancreas centers over the world. Several centers have shown very good results in simultaneous pancreas-kidney (SPK) transplant recipients receiving antithymocyte globulin induction and maintenance immunosuppression consisting of calcineurin inhibitor and mycophenolate mofetil with or without corticosteroids.

The use of sirolimus in SPK transplant patients has for the moment only been studied, with good results, in association with tacrolimus or cyclospsorine (CsA). In renal transplantation, there is also evidence that sirolimus (Rapamune) is a potent immunosuppressant that significantly reduces the incidence of acute rejection when given with CsA, effective as base therapy in the post-induction period. Because of Rapamune's effectiveness and different safety profile, it might be advantageous in terms of reduced nephrotoxicity to avoid completely calcineurin inhibitors without increased incidence of acute rejection.

To explore this further, the following study is designed to assess the use of SRL versus TAC, both treatment groups including rATG plus MMF and a 3-month course of steroids in de novo simultaneous pancreas-kidney transplant recipients.

GVAX Pancreas Vaccine With or Without CRS-207 for Advanced Pancreatic Cancer [Recruiting]

- The GVAX pancreas vaccine is made from pancreatic cancer cells. The cells are changed

in a laboratory to make a protein that helps to activate the immune system cells to recognize and attack the cancer cells. The vaccine will be given as six injections (shots) under the skin. This vaccine is experimental and it is not yet known if it will be helpful to patients with pancreatic cancer.

- CRS-207 is a weakened form of the Listeria bacteria commonly found in the environment

(called wild-type ). Wild-type Listeria can sometimes cause food poisoning and other infections. The bacteria in CRS-207 have been modified to help stimulate the immune system without causing infection.


- To test the safety and effectiveness of the GVAX pancreas vaccine with low doses of

cyclophosphamide and CRS-207.



- Have histologically proven malignant adenocarcinoma of the pancreas

- Locally advanced disease may have non-evaluable disease

- Be at least 18 years of age

- Have an Eastern Cooperative Oncology Group performance status of 0-1

- Have an anticipated life expectancy of greater than 12 weeks


- No history or evidence of brain metastases

- No allergy to both penicillin and sulfa

- No artificial joint or implant ( dental, breast, and portacaths are allowed if no

history of infection or adverse events with implants)

- No history of HIV, hepatitis B or hepatitis C

- No history of active autoimmune disease or history of autoimmune disease requiring

steroids or immunosuppressive treatment.

- No unhealed surgical wounds

- At least 28 days post surgery, steroids or investigational products.


- Participants will be screened with a physical exam and medical history. They will also

have blood and urine tests, and imaging studies.

- Participants will be in one of two treatment groups. One group will have two doses of

GVAX pancreas vaccine and chemotherapy. This will be followed by four doses of CRS-207. The other group will have six doses of GVAX pancreas vaccine with chemotherapy and no CRS-207.

- Everyone in the study will have the GVAX pancreas vaccine and chemotherapy at weeks 1

and 4 of the study. Treatment will be monitored with frequent regular tests and imaging studies.

- The first treatment group will receive CRS-207 infusions at Week 7. Infusions will be

given in weeks 7, 10, 13, and 16. Participants may need to take antibiotics at certain points during CRS-207 treatment to help clear the drug from the system.

- The second treatment group will have the vaccine and chemotherapy only at weeks 7, 10,

13, and 16.

- Participants will have a final followup exam at Week 20, with a physical exam, blood

tests, and imaging studies.

Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas [Not yet recruiting]
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improved glycemic control vs. usual in the outpatient environment.

more trials >>

Reports of Suspected Creon (Amylase / Lipase / Protease) Side Effects

Flatulence (26)Diarrhoea (25)Abdominal Pain (23)Weight Decreased (18)Drug Ineffective (15)Nausea (15)Dizziness (12)Abdominal Distension (12)Vomiting (12)Constipation (10)more >>

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015